pairment of INR23b? Glenmark Pharma (GNP) posted lower-than-expected revenue in 4QFY24.However, it delivered better-than-expected profitability for the quarter,aided by an improved product mix and lower raw material costs. Having saidthis, GNP has taken a considerable impairment charge on manufacturingfacilities and certain intangibles (~INR32b) during the quarter